| Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. | |
| | |
MedLine Citation:
|
PMID: 20093897 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the efficacy and safety of ulipristal acetate as emergency contraception in women presenting 48-120 hours after receiving ulipristal acetate for unprotected intercourse. METHODS: Women aged 18 years or older with regular cycles who presented for emergency contraception 48 to 120 hours after unprotected intercourse were enrolled in 45 Planned Parenthood clinics and treated with a single dose of 30 mg ulipristal acetate. Pregnancy status was determined by high-sensitivity urinary human chorionic gonadotropin testing and return of menses. RESULTS: A total of 1,241 women were evaluated for efficacy. Twenty-six were pregnant at follow-up, for a pregnancy rate of 2.1% (95% confidence interval 1.4-3.1%). These results satisfy the protocol-defined statistical criteria for success because the pregnancy rate was lower than both the estimated expected pregnancy rate and a predefined clinical irrelevance threshold. In addition, efficacy did not decrease over time: pregnancy rates were 2.3% (1.4-3.8%), 2.1% (1.0-4.1%), and 1.3% (0.1-4.8%) for intervals of 48 to 72 hours, more than 72 to 96 hours, and more than 96 to 120 hours, respectively. Adverse events were mainly mild or moderate, the most frequent being headache, nausea, and abdominal pain. Cycle length increased a mean of 2.8 days, whereas the duration of menstrual bleeding did not change. CONCLUSION: Ulipristal acetate is effective and well-tolerated for emergency contraception 48-120 hours after unprotected intercourse. LEVEL OF EVIDENCE: II. |
| | |
Authors:
|
Paul Fine; Henri Mathé; Savita Ginde; Vanessa Cullins; Johanna Morfesis; Erin Gainer |
Related Documents
:
|
20670097 - How do levonorgestrel-only emergency contraceptive pills prevent pregnancy? some consid... 19492697 - Adolescent contraceptive care for the practicing pediatrician. 4018277 - Absence of chorionic gonadotropin in sera of women who use intrauterine devices. 20230337 - State-of-the-art of non-hormonal methods of contraception: iii. intrauterine devices. 12828107 - Hyperlipemic pancreatitis and pseudocyst formation in late pregnancy. 22284667 - Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 115 ISSN: 1873-233X ISO Abbreviation: Obstet Gynecol Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-22 Completed Date: 2010-02-16 Revised Date: 2011-02-08 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 257-63 Citation Subset: AIM; IM |
Affiliation:
|
Planned Parenthood of Houston & Southeast Texas, Houston, Texas, USA. paul.fine@pphset.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Contraception, Postcoital*
/
adverse effects Contraceptives, Postcoital, Hormonal* / adverse effects Female Humans Menstrual Cycle / drug effects Norpregnadienes* Pregnancy |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptives, Postcoital, Hormonal; 0/Norpregnadienes; 0/ulipristal; 0/ulipristal acetate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and...
Next Document: Alternatives to a routine follow-up visit for early medical abortion.